While comparison of patients with matched controls suggests reduced BCL2 levels in MJD patients (p = 0.041) (Figure 2B), BCL2 transcript abundance displays low accuracy to discriminate patients from matched controls (AUC = 0.64 (0.51–0.77), p = 0.030). This evidence concerns the gene BCL2 and Machado-Joseph disease.